Cardiac Contractility Modulation for Patients with Heart Failure
DOI:
https://doi.org/10.2015/hc.v9i1%20Sup.632Keywords:
heart failure, device therapy, cardiac contractility modulationAbstract
A substantial proportion of patients with heart failure remain either not eligible for cardiac resynchronization therapy (CRT) or do not respond to this therapy. CRT is indicated in patients with prolonged QRS duration (>120 ms). However, up to 60% of patients with heart failure have a normal QRS duration and are not appropriate candidates for CRT. In addition, a significant number of patients (25-30%) who meet the current indications to CRT therapy are non-responders. New device-based therapies including cardiac contractility modulation (CCM) have been developed over the last decade.
Â
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
